Business Description
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 2.39
Total Equity: $789.18M
Shares: 134,684,000
Total Debt: $1.01B
Cash: $1.66B
EBITDA: $631.44M
Total Debt: $1.01B
Cash: $1.66B
Revenue: $3.71B
Revenue: $3.71B
Revenue: $3.71B
Total Equity: $789.18M
Tax Rate: 2.9%
Equity: $789.18M
Total Debt: $1.01B
Cash: $1.66B
Current Liabilities: $1.47B
Long-Term Debt: $1.01B
Total Debt: $1.01B
Total Equity: $789.18M
Shares: 134,684,000
Shares: 134,684,000
CapEx: -$58.70M
Shares: 134,684,000
Stock Price: $291.37
Net Income: $313.75M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:50pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $844.3M | $1.0B | $1.8B | $2.2B | $3.7B |
| Cost of Revenue | $140.1M | $168.8M | $310.4M | $323.4M | $677.2M |
| Gross Profit | $704.1M | $868.6M | $1.5B | $1.9B | $3.0B |
| Operating Expenses | $1.4B | $1.7B | $1.8B | $2.1B | $2.5B |
| Operating Income | -$708.7M | -$785.1M | -$282.2M | -$176.9M | $501.6M |
| Net Income | -$852.8M | -$1.1B | -$440.2M | -$278.2M | $313.7M |
| EBITDA | -$661.6M | -$926.6M | -$258.2M | -$178.8M | $631.4M |
| EPS | $-7.20 | $-9.30 | $-3.52 | $-2.18 | $2.39 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $820.0M | $866.4M | $812.7M | $966.4M | $1.7B |
| Total Current Assets | $2.8B | $2.7B | $3.0B | $3.3B | $4.1B |
| Total Assets | $3.6B | $3.5B | $3.8B | $4.2B | $5.0B |
| Current Liabilities | $695.7M | $767.9M | $967.8M | $1.2B | $1.5B |
| Long-Term Debt | $675.7M | $1.0B | $1.0B | $2.4B | $1.0B |
| Total Liabilities | $3.1B | $3.7B | $4.1B | $4.2B | $4.2B |
| Total Equity | $588.2M | -$158.2M | -$220.6M | $67.1M | $789.2M |
| Retained Earnings | -$5.4B | -$6.6B | -$7.0B | -$7.3B | -$6.7B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$641.7M | -$541.3M | $104.2M | -$8.3M | $524.1M |
| Capital Expenditure | -$76.4M | -$72.1M | -$62.2M | -$34.3M | -$58.7M |
| Free Cash Flow | -$718.1M | -$613.3M | $41.9M | -$42.6M | $465.4M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $323.1M | $46.4M | -$53.7M | $153.8M | $690.2M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 2:22am (7h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$7.3B $6.7B – $9.0B
|
$8.7B $8.7B – $8.7B
|
$10.2B $9.6B – $11.9B
|
$11.7B $11.1B – $13.7B
|
| EBITDA |
-$2.5B -$3.1B – -$2.3B
|
-$3.0B -$3.0B – -$3.0B
|
-$3.5B -$4.1B – -$3.3B
|
-$4.1B -$4.7B – -$3.8B
|
| Net Income |
$1.5B $1.2B – $1.7B
|
$2.0B $1.2B – $2.6B
|
$2.1B $2.0B – $2.6B
|
$2.6B $2.4B – $3.2B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:50pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +22.9% | +76.2% | +23.0% | +65.2% |
| Gross Profit Growth | +23.4% | +74.8% | +26.8% | +57.8% |
| Operating Income Growth | -10.8% | +64.1% | +37.3% | +383.6% |
| Net Income Growth | -32.6% | +61.1% | +36.8% | +212.8% |
| EBITDA Growth | -40.1% | +72.1% | +30.7% | +453.1% |
Narrative Economics
market-narrative step).